Plerixafor-AFT

In combination w/ granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of hematopoietic stem cells (HSCs) to the peripheral blood for collection & subsequent autologous transplantation in adult patients w/ lymphoma or multiple myeloma whose cells mobilise poorly; in childn w/ lymphoma or solid malignant tumours who pre-emptively when circulating stem cell count on predicted day of collection after adequate mobilization w/ G-CSF (w/ or w/o chemotherapy) is expected to be insufficient w/ regards to desired HSCs yield or those who previously failed to collect sufficient HSCs.

SC Administer 6-11 hr prior to initiation of each aphresis following 4 days of G-CSF pre-treatment. Adult weighing >83 kg 0.24 mg/kg, ≤83 kg 20 mg fixed dose or 0.24 mg/kg. Paed 1 to <18 yr 0.24 mg/kg. Renal impairment CrCl <50 mL/min Max: 27 mg/day, 20-50 mL/min Reduce dose by ¹/₃ to 0.16 mg/kg/day.

Hypersensitivity.

Supportive Care Therapy

L03AX16 - plerixafor ; Belongs to the class of other immunostimulants.

POM